Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.83 HKD | -1.43% | -5.29% | -27.26% |
May. 02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
Apr. 10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.26% | 606M | |
+60.65% | 62.59B | |
-3.24% | 41.18B | |
+44.70% | 40.29B | |
-8.29% | 27.9B | |
+13.42% | 26.21B | |
-22.07% | 19.09B | |
+4.52% | 13.08B | |
+24.83% | 12.26B | |
+27.52% | 12.05B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Nomura Adjusts Alphamab Oncology's Price Target to HK$13.22 From HK$13.89, Keeps at Buy